Novavax, Inc., today announced its financial results for the fourth quarter and twelve months ended December 31, 2016. Continued execution of the global Phase 3 PrepareTM clinical trial to prevent RSV in infants via maternal immunization.
Category: Novavax
Short Interest in Novavax, Inc. (NVAX) Decreases By 1.9%
Novavax, Inc. was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 63,797,973 shares, a drop of 1.9% from the January 13th total of 65,010,684 shares.
Novavax Inc. (NVAX) Stock Rating Reaffirmed by Cantor Fitzgerald
‘s stock had its “hold” rating restated by research analysts at Cantor Fitzgerald in a research report issued on Friday. They currently have a $2.00 price objective on the biopharmaceutical company’s stock.